000 04409nam a22005295i 4500
001 978-3-030-02505-2
003 DE-He213
005 20210201191345.0
007 cr nn 008mamaa
008 181211s2018 gw | s |||| 0|eng d
020 _a9783030025052
_9978-3-030-02505-2
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
082 0 4 _a614.5999
_223
245 1 0 _aImmunotherapy
_h[electronic resource] /
_cedited by Aung Naing, Joud Hajjar.
250 _a2nd ed. 2018.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2018.
300 _aVIII, 182 p. 12 illus., 8 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v995
500 _aAcceso multiusuario
505 0 _aOverview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies .
520 _aThe second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
541 _fUABC ;
_cTemporal ;
_d01/01/2021-12/31/2023.
650 0 _aCancer research.
650 1 4 _aCancer Research.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B11001
700 1 _aNaing, Aung.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aHajjar, Joud.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783030025045
776 0 8 _iPrinted edition:
_z9783030025069
776 0 8 _iPrinted edition:
_z9783030378561
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v995
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-030-02505-2
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c242539
_d242538